<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451383</url>
  </required_header>
  <id_info>
    <org_study_id>2008-363</org_study_id>
    <nct_id>NCT03451383</nct_id>
  </id_info>
  <brief_title>Older Breast Cancer Patients: Risk for Cognitive Decline</brief_title>
  <acronym>TLC</acronym>
  <official_title>Older Breast Cancer Patients: Risk for Cognitive Decline. The Thinking and Living With Cancer (TLC) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the impact of systemic therapy on cognition in older&#xD;
      breast cancer patients, explore which domains are most affected, measure associations between&#xD;
      cognitive decline and QOL, and describe how APOE and COMT polymorphisms, inflammatory&#xD;
      biomarkers and physical activity moderate cognitive outcomes. This study is being done&#xD;
      nationally, with recruiting sites at Georgetown University, Montgomery General Hospital,&#xD;
      Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists,&#xD;
      Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center,&#xD;
      Hackensack University Medical Center, Indiana University and University of California, Los&#xD;
      Angeles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer is the leading cause of death in the US and breast cancer is the second most common&#xD;
      cancer among women in our country. Older women (women 60 and older) presently account for&#xD;
      nearly half of all new cases of breast cancer. With the &quot;graying of America&quot; and advances in&#xD;
      treatment for breast cancer, the absolute number of older women undergoing breast cancer&#xD;
      treatment and surviving their disease will almost double by the year 2030. Systemic hormonal&#xD;
      and non-hormonal chemotherapy is credited with improvements in survival, and rates of use of&#xD;
      these modalities have increased substantially over the past two decades. Preliminary work has&#xD;
      found that older women are interested in chemotherapy even for small returns in survival&#xD;
      extension. However, cognitive impairment has been demonstrated in most studies of breast&#xD;
      cancer systemic treatments, but virtually all of this research has been conducted in younger&#xD;
      populations. Since aging itself is associated with cognitive declines, it seems very likely&#xD;
      that older women are particularly vulnerable to the adverse cognitive effects of systemic&#xD;
      therapy; our preliminary work strongly suggests that this is the case, but this has never&#xD;
      been empirically tested.&#xD;
&#xD;
      This study will be the first large-scale, prospective, controlled investigation to evaluate&#xD;
      cognitive changes in older cancer patients and it will provide the basis for the next&#xD;
      generation of mechanistic, treatment and intervention studies. These will be important since&#xD;
      data from younger patients cannot be directly translated into the older population.&#xD;
      Investigators will use the vulnerability model of cancer survivorship to prospectively&#xD;
      describe the magnitude of systemic therapy effects on cognition in older (age &gt;60 years)&#xD;
      breast cancer patients over a 60 month period, test associations between cognition and&#xD;
      quality of life (QOL) and evaluate whether APOE and COMT polymorphisms, inflammatory&#xD;
      biomarkers and physical activity moderate cognitive outcomes.&#xD;
&#xD;
      To achieve these objectives, investigators have assembled a multi-disciplinary team of&#xD;
      oncologists, geriatricians, neurologists, neuro- and cognitive psychologists, behavioral&#xD;
      scientists and consumers from Lombardi Comprehensive Cancer Center (LCCC), Memorial&#xD;
      Sloan-Kettering Cancer Center (MSKCC), Moffitt Cancer Center, City of Hope National Medical&#xD;
      Center (COH), Hackensack University Medical Center (HUMC), Indiana University (IU), Boston&#xD;
      University (BU), University of California (UCLA), University of South Florida (USF) and their&#xD;
      satellites, will work together to prospectively enroll 425 newly diagnosed older breast&#xD;
      cancer cases from LCCC, MSKCC, Moffitt, COH, HUMC, IU and tertiary referral centers with high&#xD;
      volumes. An equal number of non-cancer friend controls will be recruited. Friend controls&#xD;
      were chosen since they will be similar to patients in most ways except for exposure to cancer&#xD;
      and its treatments and they should be motivated to participate. If friends are not available,&#xD;
      controls matched to cases on age, education, race, and area (DC/NY/FL/CA/NJ/IU) will be&#xD;
      recruited from the community.&#xD;
&#xD;
      Investigators will administer baseline neuropsychological testing prior to any systemic&#xD;
      treatment (or at enrollment for controls), survey women about subjective cognitive function,&#xD;
      psychosocial factors, QOL and activities of daily living (IADLS). Investigators will abstract&#xD;
      clinical data from medical records. Investigators will obtain blood or saliva to test for&#xD;
      APOE and COMT polymorphisms at enrollment; these results will not be provided to participants&#xD;
      since this is considered a research test). Subjects have the option to provide blood for&#xD;
      biomarker research and for biobanking. Subjects also have the option of participating in&#xD;
      physical activity monitoring for one week. Subjects will also have the option to participate&#xD;
      in neuroimaging. Investigators conduct follow-up interviews and repeat the neuropsychological&#xD;
      testing and optional neuroimaging 12 months after baseline assessment; this time point&#xD;
      corresponds to 3-6 months post-treatment among women who receive chemotherapy. Our primary&#xD;
      cognitive outcome will be change in summary score on tests in the Attention, Working Memory,&#xD;
      and Psychomotor Speed Domain. In secondary analyses, investigators examine changes in scores&#xD;
      on 4 additional domains to assess broader cognitive function and examine questions of&#xD;
      differential impact: Language; Executive Functioning; Learning and Memory; Visual-spatial.&#xD;
&#xD;
      Data from this study will guide future interventions to better select older women for whom&#xD;
      the benefits of systemic therapy outweigh the harms and to develop approaches to mitigate&#xD;
      negative consequences of systemic treatment when it is indicated, improving the quality of&#xD;
      care for the growing population of older breast cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Attention</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: NAB Digits Forward and Backward</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Processing Speed</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: Trailmaking A and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Processing Speed</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: Digit Symbol Subtest - Wechsler Adult Intelligence Test-III</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Processing Speed</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using assessment: The Timed Instrumental Activities of Daily Living</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: Trailmaking A and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: Digit Symbol Subtest - Wechsler Adult Intelligence Test-III</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: Controlled Oral Word Association Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: NAB Driving Scenes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Executive Function</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: NAB Figure Drawing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Learning</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: Logical Memory I and II (Wechsler Memory Scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Learning</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using neuropsychological test: NAB List Learning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using Functional Assessment of Cancer Therapy-Breast quality of life measure (FACT-B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using Medical Outcome Study measure (MOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using Short Form Health Survey measure (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cancer-related symptoms (including fatigue, sleep, pain, anxiety and depression)</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using survey data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of aging (genotype, inflammatory biomarkers, telomere length, p16, miRNA)</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using annual biospecimen collection of blood or saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using self-report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity</measure>
    <time_frame>Baseline and annually up to 5 years</time_frame>
    <description>Using actigraphy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Cancer, Breast</condition>
  <condition>Age-related Cognitive Decline</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Case</arm_group_label>
    <description>Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Cancer Controls</arm_group_label>
    <description>Women age 60+ with no diagnosis of breast cancer.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A total of up to 27ml of blood will be collected at each time point by trained staff for APOE&#xD;
      and COMT DNA testing, inflammatory biomarkers and for storage of DNA for future tests. 2-3&#xD;
      6mL lavender top vacutainer tubes containing ethylenediamine tetraaceticacid (EDTA) will be&#xD;
      used for DNA extraction, biobanking and inflammatory biomarkers. 1 4ml CPT tube will be&#xD;
      collected for biobanking. Up to 2 2.5ml PAXgene tubes will be collected for future DNA and&#xD;
      RNA research. If a blood draw is not possible, up to 2ml of saliva will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3 and matched controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For cancer patients, eligibility includes:&#xD;
&#xD;
          -  being female&#xD;
&#xD;
          -  Age 60+ at diagnosis of a new primary histological confirmed adenocarcinoma breast&#xD;
             cancer&#xD;
&#xD;
          -  AJCC stages 0-3 or planning neoadjuvant therapy&#xD;
&#xD;
          -  In the judgment of the consenting professional, able to communicate well enough in&#xD;
             English through verbal and written communication to complete the study assessments and&#xD;
             provide informed consent&#xD;
&#xD;
          -  If currently taking psychoactive medications (including, but not limited to&#xD;
             anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at&#xD;
             least two months prior to enrollment.&#xD;
&#xD;
          -  Participant report of no previous or current chemotherapy or hormonal treatment use&#xD;
             (anastrazole, exemestane, etc.) This does not include hormonal replacement therapy,&#xD;
             synthetic thyroid hormones, etc.&#xD;
&#xD;
        For controls, eligibility includes:&#xD;
&#xD;
          -  being female&#xD;
&#xD;
          -  Age 60+&#xD;
&#xD;
          -  In the judgment of the consenting professional, able to communicate well enough in&#xD;
             English through verbal and written communication to complete the study assessments and&#xD;
             provide informed consent&#xD;
&#xD;
          -  If currently taking psychoactive medications (including, but not limited to&#xD;
             anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at&#xD;
             least two months prior to enrollment.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        We apply the same exclusion criteria for patients and controls.&#xD;
&#xD;
          -  Participant report of a history of formal diagnosis of neurological problems (i.e.&#xD;
             Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure&#xD;
             Disorders, brain tumors, etc.)&#xD;
&#xD;
          -  Participant report of surgery on the brain for any reason (cancerous or non-cancerous&#xD;
             tumors, subdural hematomas, AV malformations, increased intracranial pressure, etc.)&#xD;
&#xD;
          -  Participant report of a history of stroke (with the exception of TIA if â‰¥1 year ago)&#xD;
&#xD;
          -  Participant report of HIV/AIDS&#xD;
&#xD;
          -  Participant report of moderate to severe head trauma (loss of consciousness &gt; 60 min&#xD;
             or with evidence of structural brain changes on imaging)&#xD;
&#xD;
          -  History of major psychiatric disorder (DSM-IV Axis 1) (i.e. major depressive disorder&#xD;
             (untreated or poorly treated), bipolar disorders, schizophrenia, or substance abuse&#xD;
             disorders (self-reported and/or stated in medical record).&#xD;
&#xD;
          -  Participant report of a history of prior breast or other cancer with the exception of&#xD;
             non-melanoma skin cancer. An exception for cases only: women who completed treatment&#xD;
             for a previous cancer at least 5 years ago and have not undergone any chemotherapy or&#xD;
             hormonal therapy. This previous cancer cannot be breast cancer.&#xD;
&#xD;
          -  Participant report of previous or current chemotherapy or hormonal therapy use&#xD;
&#xD;
          -  Participant use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab&#xD;
             (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide&#xD;
             (Cytoxan, Neosar) for Lupus.&#xD;
&#xD;
          -  Visual or hearing impairment that would preclude ability to complete interviews or&#xD;
             neuropsychological testing, such as significant macular degeneration or being unable&#xD;
             to correct hearing with hearing aides&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  To participate in the optional neuroimaging portion of the study:&#xD;
&#xD;
        Participant cannot be claustrophobic Participant cannot have a pacemaker, aneurysm clip or&#xD;
        other implants that are not MRI safe Participant cannot have any type of implanted&#xD;
        electrical device&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female breast cancer cases and female matched non-cancer controls</gender_description>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanne Mandelblatt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lombardi Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanne Mandelblatt</last_name>
    <phone>2026870801</phone>
    <email>mandelbj@georgetown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meghan Mihalache</last_name>
    <phone>2026878247</phone>
    <email>mem323@georgetown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Jeanne Mandelblatt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>cognitive decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03451383/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

